1
|
Neskovic-Konstantinovic Z, Nooij M, Khaled H, De Valk B, Vermorken J, Welnicka-Jaskiewicz M, Piccart M, Marreaud S, Bogaerts J, Cameron D. Safety and efficacy of combined trastuzumab and CMF therapy in women with metastatic breast cancer: EORTC protocol 10995. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1040 Background: Safety and efficacy of classical CMF combined with 3-weekly Trastuzumab (T), followed by T alone in metastatic breast cancer (MBC). Methods: Patients (pts) with previously treated MBC were enrolled into a Phase II study of T (4 mg/kg then by 2 mg/kg) IV weekly plus CMF, Bonadonna regimen, for a maximum of 8 cycles (cy), followed by T alone (6 mg/kg) IV 3 weekly. Entry criteria included HER2 overexpression, limited anthracycline (A) exposure, normal baseline LVEF and measurable disease (RECIST). Cardiac endpoints were defined as: symptomatic CHF or LVEF drop by ≥ 15% from baseline or to ≥ 5% below lower limit. Results: The trial was closed to recruitment in January 2006, 12 pts are still on treatment. Seventy one pts were entered with a median age of 54 (range 31–75). Forty-one pts had prior CT (32 A), of which 26 adjuvant, 6 MBC, and 9 both adjuvant and MBC. Median PS was 0, 52 pts had visceral disease with a median interval from diagnosis to first relapse of 33.4 months (mo). Out of 70 pts receiving T+CMF (33 pts with 8 cy), 42 continued with T alone for a median duration of 7 cy. Eleven pts discontinued treatment for toxicity (9 on T+CMF, 2 on T alone). To date, the overall response rate is 55% (31/56 pts): 55% (23/42) 1st line; 57% (8/14) 2nd line. An independent review of responses is on-going. Median time to response was 2 mo, median duration of response was 8.3 mo and the median progression free survival was 9.2 mo. The most common grade 3–4 toxicity was neutropenia (53 %). Fourteen pts had cardiac toxicities, one NYHA grade 2 CHF, 6 pts with a drop in LVEF of 15% from baseline after a median of 3 mo of treatment, 9 pts with a drop in LVEF of 5% below LLN, after a median of 8 mo of treatment. The other toxicities included one grade 3 arrhythmia, two grade 3 hypertension, one grade 2 SVT, one grade 3 thrombosis, and one grade 2 dyspnea. One pt previously exposed to A had NYHA grade 4 CHF one year after treatment discontinuation. Conclusions: Combination of T+CMF regimen is feasible treatment for HER2+ MBC patients. The safety profile was acceptable, with cardiac toxicity and neutropenia within previously reported range. Drops in LVEF were mostly asymptomatic irrespective of previous exposure to A. Preliminary response data confirm good efficacy of CMF+T in MBC patients. [Table: see text]
Collapse
Affiliation(s)
- Z. Neskovic-Konstantinovic
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| | - M. Nooij
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| | - H. Khaled
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| | - B. De Valk
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| | - J. Vermorken
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| | - M. Welnicka-Jaskiewicz
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| | - M. Piccart
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| | - S. Marreaud
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| | - J. Bogaerts
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| | - D. Cameron
- Institute of Oncology & Radiolgy, Belgrade, Serbia and Montenegro; Leiden University Medical Centre, Leiden, The Netherlands; National Cancer Institute, Cairo, Egypt; Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands; Universitair Ziekenhuis Antwerpen, Antwerp, Belgium; Medical University of Gdansk, Gdansk, Poland; Istitut Jules Bordet, Bruxelles, Belgium; EORTC, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom
| |
Collapse
|
2
|
Beex L, Rose C, Mouridsen H, Jassem J, Nooij M, Estape J, Paridaens R, Piccart M, Gorlia T, Lardenoije S, Baila L. Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863). Eur J Cancer 2006; 42:3178-85. [PMID: 17045796 DOI: 10.1016/j.ejca.2006.08.020] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2006] [Revised: 08/29/2006] [Accepted: 08/31/2006] [Indexed: 11/20/2022]
Abstract
BACKGROUND Continuous ligand depletion of endocrine responsive tumours may enhance resistance to therapy. Intermittent treatment with tamoxifen (T) was considered to mimic (incomplete) ligand depletion and reintroduction. Furthermore it was postulated that alternating tamoxifen with a non-cross resistant endocrine modality could (further) postpone hormone resistance. PATIENTS AND METHODS Postmenopausal patients with advanced breast cancer who did not progress after 4 months of first line T therapy were randomised to continue T (40 mg daily) or to 2 monthly intermittent T or intermittent/alternated T and medroxyprogesterone acetate (MPA, 300 mg daily). At progression during break or during MPA, T should be reintroduced. Endpoints of the study were progression free survival (PFS), time to resistance to tamoxifen and overall survival (OS). RESULTS Of 593 registered patients, 276 were randomised. After 8 years follow-up the median PFS for continuous T, intermittent T and intermittent/alternated T and MPA was 11.0 (8.1-15.2), 8.0 (6.2-12.4) and 10.8 (7.1-16.7) months, respectively (NS). Resistance to tamoxifen was established only in 84%, 70% and 55% of patients in the three treatment arms, respectively. The median times from randomisation to resistance to tamoxifen were 12.5 (9.1-21.1), 13.2 (8.8-19.8) and 24.0 (16.9-60.9) months, respectively (p<0.001), without translation in differences in survival times. CONCLUSION Intermittent T or intermittent/alternated T and MPA had no impact on PFS or OS as compared with classical continuous T in patients with advanced breast cancer. Intermittent/alternated T and MPA resulted in prolonged time to resistance to T, but this might partly be due to bias by omittance of the proof of tamoxifen resistance in a high proportion of the patients in this treatment arm.
Collapse
Affiliation(s)
- L Beex
- Department of Medical Oncology, 452 Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands, and Department of Oncology, Lund University Hospital, Sweden.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Paridaens R, Therasse P, Dirix L, Beex L, Piccart M, Cameron D, Cufer T, Roozendaal K, Nooij M, Mattiacci MR. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.515] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Paridaens
- Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; EORTC Data Center, Brussels, Belgium; Algemeen Ziekenhuis Sint-Augustinus, Wilrijk, Belgium; Universitair Ziekenhuis, Nijmegen, Netherlands; Institut Jules Bordet, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom; Institute of Oncology, Ljubljana, Slovenia; Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; Leiden University Medical Centre, Leiden, Netherlands
| | - P. Therasse
- Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; EORTC Data Center, Brussels, Belgium; Algemeen Ziekenhuis Sint-Augustinus, Wilrijk, Belgium; Universitair Ziekenhuis, Nijmegen, Netherlands; Institut Jules Bordet, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom; Institute of Oncology, Ljubljana, Slovenia; Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; Leiden University Medical Centre, Leiden, Netherlands
| | - L. Dirix
- Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; EORTC Data Center, Brussels, Belgium; Algemeen Ziekenhuis Sint-Augustinus, Wilrijk, Belgium; Universitair Ziekenhuis, Nijmegen, Netherlands; Institut Jules Bordet, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom; Institute of Oncology, Ljubljana, Slovenia; Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; Leiden University Medical Centre, Leiden, Netherlands
| | - L. Beex
- Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; EORTC Data Center, Brussels, Belgium; Algemeen Ziekenhuis Sint-Augustinus, Wilrijk, Belgium; Universitair Ziekenhuis, Nijmegen, Netherlands; Institut Jules Bordet, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom; Institute of Oncology, Ljubljana, Slovenia; Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; Leiden University Medical Centre, Leiden, Netherlands
| | - M. Piccart
- Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; EORTC Data Center, Brussels, Belgium; Algemeen Ziekenhuis Sint-Augustinus, Wilrijk, Belgium; Universitair Ziekenhuis, Nijmegen, Netherlands; Institut Jules Bordet, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom; Institute of Oncology, Ljubljana, Slovenia; Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; Leiden University Medical Centre, Leiden, Netherlands
| | - D. Cameron
- Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; EORTC Data Center, Brussels, Belgium; Algemeen Ziekenhuis Sint-Augustinus, Wilrijk, Belgium; Universitair Ziekenhuis, Nijmegen, Netherlands; Institut Jules Bordet, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom; Institute of Oncology, Ljubljana, Slovenia; Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; Leiden University Medical Centre, Leiden, Netherlands
| | - T. Cufer
- Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; EORTC Data Center, Brussels, Belgium; Algemeen Ziekenhuis Sint-Augustinus, Wilrijk, Belgium; Universitair Ziekenhuis, Nijmegen, Netherlands; Institut Jules Bordet, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom; Institute of Oncology, Ljubljana, Slovenia; Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; Leiden University Medical Centre, Leiden, Netherlands
| | - K. Roozendaal
- Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; EORTC Data Center, Brussels, Belgium; Algemeen Ziekenhuis Sint-Augustinus, Wilrijk, Belgium; Universitair Ziekenhuis, Nijmegen, Netherlands; Institut Jules Bordet, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom; Institute of Oncology, Ljubljana, Slovenia; Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; Leiden University Medical Centre, Leiden, Netherlands
| | - M. Nooij
- Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; EORTC Data Center, Brussels, Belgium; Algemeen Ziekenhuis Sint-Augustinus, Wilrijk, Belgium; Universitair Ziekenhuis, Nijmegen, Netherlands; Institut Jules Bordet, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom; Institute of Oncology, Ljubljana, Slovenia; Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; Leiden University Medical Centre, Leiden, Netherlands
| | - M.-R. Mattiacci
- Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; EORTC Data Center, Brussels, Belgium; Algemeen Ziekenhuis Sint-Augustinus, Wilrijk, Belgium; Universitair Ziekenhuis, Nijmegen, Netherlands; Institut Jules Bordet, Brussels, Belgium; Western General Hospital, Edinburgh, United Kingdom; Institute of Oncology, Ljubljana, Slovenia; Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; Leiden University Medical Centre, Leiden, Netherlands
| |
Collapse
|
4
|
Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, Lohrisch C, Cufer T, Lobelle JP, Mattiaci MR, Piccart M, Paridaens R. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Ann Oncol 2004; 15:211-7. [PMID: 14760111 DOI: 10.1093/annonc/mdh064] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
BACKGROUND The impact of aromatase inhibitors (AIs) on non-cancer-related outcomes, which are known to be affected by oestrogens, has become increasingly important in postmenopausal women with hormone-dependent breast cancer. So far, data related to the effect of AIs on lipid profile in postmenopausal women is scarce. This study, as a companion substudy of an EORTC phase II trial (10951), evaluated the impact of exemestane, a steroidal aromatase inactivator, on the lipid profile of postmenopausal metastatic breast cancer (MBC) patients. PATIENTS AND METHODS The EORTC trial 10951 randomised 122 postmenopausal breast cancer patients to exemestane (E) 25 mg (n = 62) or tamoxifen (T) 20 mg (n = 60) once daily as a first-line treatment in the metastatic setting. Exemestane showed promising results in all the primary efficacy end points of the trial (response rate, clinical benefit rate and response duration), and it was well tolerated with low incidence of serious toxicity. As a secondary end point of this phase II trial, serum triglycerides (TRG), high-density lipoprotein cholesterol (HDL), total cholesterol (TC), lipoprotein a (Lip a), and apolipoproteins (Apo) B and A1 were measured at baseline and while on therapy (at 8, 24 and 48 weeks) to assess the impact of exemestane and tamoxifen on serum lipid profiles. Of the 122 randomised patients, those who had baseline and at least one other lipid assessment are included in the present analysis. The patients who received concomitant drugs that could affect lipid profile are included only if these drugs were administered throughout the study treatment. Increase or decrease in lipid parameters within 20% of baseline were considered as non-significant and thus unchanged. RESULTS Seventy-two patients (36 in both arms) were included in the statistical analysis. The majority of patients had abnormal TC and normal TRG, HDL, Apo A1, Apo B and Lip a levels at baseline. Neither exemestane nor tamoxifen had adverse effects on TC, HDL, Apo A1, Apo B or Lip a levels at 8, 24 and 48 weeks of treatment. Exemestane and tamoxifen had opposite effects on TRG levels: exemestane lowered while tamoxifen increased TRG levels over time. There were too few patients with normal baseline TC and abnormal TRG, HDL, Apo A1, Apo B and Lip a levels to allow for assessment of E's impact on these subsets. The atherogenic risk determined by Apo A1:Apo B and TC:HDL ratios remained unchanged throughout the treatment period in both the E and T arms. CONCLUSIONS Overall, exemestane has no detrimental effect on cholesterol levels and the atherogenic indices, which are well-known risk factors for coronary artery disease. In addition, it has a beneficial effect on TRG levels. These data, coupled with E's excellent efficacy and tolerability, support further exploration of its potential in the metastatic, adjuvant and chemopreventive setting.
Collapse
Affiliation(s)
- G Atalay
- Jules Bordet Institute, Brussels, Belgium
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Anninga JK, van de Vijver MJ, Cleton-Jansen AM, Kristel PMP, Taminiau AHM, Nooij M, Egeler RM, Hogendoorn PCW. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 2004; 40:963-70. [PMID: 15093570 DOI: 10.1016/j.ejca.2003.10.025] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2003] [Accepted: 10/15/2003] [Indexed: 11/23/2022]
Abstract
The aim of our study was to determine whether or not the tyrosine kinase receptor, HER2 (also known as ErbB2/Her2/neu), is overexpressed in human osteosarcomas (OS). We studied 15 biopsy and 18 resection specimens at the mRNA and protein levels. HER2 status in the OS specimens was assessed by immunohistochemistry (IHC) and quantitative Real-Time Polymerase chain reaction (PCR). In moderately immunopositive cases fluorescent in situ hybridisation (FISH) analysis was used in order to identify any possible gene amplification. 27 samples were evaluable for IHC and only 1 case showed a moderately positive membrane staining. The remaining samples showed no staining or focal cytoplasmic staining (2 samples). In the moderately positive case, FISH analysis showed no HER-2 gene amplification. There was also no overexpression of HER2 mRNA suggesting this sample was a false-positive immunostain. HER2 mRNA expression was present in all samples at a similar level to that in the breast cancer cell line, MCF7, which does not overexpress HER2 and was used as a negative control. In conclusion, this study shows that HER2 mRNA or membranous HER2 protein overexpression is absent in human OS. We noted various inconsistencies in previous published studies, with regard to methodology and the interpretation of the results based on poor methodology. We therefore conclude that the positive data with regard to HER2 overexpression reported in these previous studies is not reliable. Our results suggest that the monoclonal antibody trastuzumab (Herceptin(R)), directed against the HER2-receptor, is not likely to be an effective therapeutic agent in OS.
Collapse
Affiliation(s)
- J K Anninga
- Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Leiden University Medical Center, J6S, PO Box 9600, 2300 RC Leiden, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Duchateau L, Hamilton A, Lobelle JP, Piccart M. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003; 14:1391-8. [PMID: 12954578 DOI: 10.1093/annonc/mdg362] [Citation(s) in RCA: 193] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Women with hormone-responsive metastatic breast cancer (MBC) may respond to or have stable disease with a number of hormone therapies. We explored the efficacy and safety of the steroidal aromatase inactivator exemestane as first-line hormonal therapy in MBC in postmenopausal women. PATIENTS AND METHODS Patients with measurable disease were eligible if they had received no prior hormone therapy for metastatic disease and had hormone receptor positive disease or hormone receptor unknown disease with a long disease-free interval from adjuvant therapy. They were randomized to tamoxifen 20 mg/day or exemestane 25 mg/day in this open-label study. RESULTS Blinded independently reviewed response rates for exemestane and tamoxifen were 41% and 17%, respectively. Fifty-seven per cent of exemestane- and 42% of tamoxifen-treated patients experienced clinical benefit, defined as complete or partial response, or disease stabilization lasting at least 6 months. There was a low incidence of severe flushing, sweating, nausea and edema in women who received exemestane. One exemestane-treated patient had a pulmonary embolism with grade 4 dyspnea. CONCLUSIONS Exemestane is well tolerated and active in the first-line treatment of hormone-responsive MBC. An ongoing EORTC phase III trial is comparing the efficacy, measuring time-to-disease progression, of exemestane and tamoxifen.
Collapse
Affiliation(s)
- R Paridaens
- Universitair Ziekenhuis, Gasthuisberg, Leuven, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Aapro M, van Wijk F, Bolis G, Chevallier B, van der Burg M, Poveda A, de Oliveira C, Tumolo S, Scotto di Palumbo V, Piccart M, Franchi M, Zanaboni F, Lacave A, Fontanelli R, Favalli G, Zola P, Guastalla J, Rosso R, Marth C, Nooij M, Presti M, Scarabelli C, Splinter T, Ploch E, Beex L, ten Bokkel Huinink W, Forni M, Melpignano M, Blake P, Kerbrat P, Mendiola C, Cervantes A, Goupil A, Harper P, Madronal C, Namer M, Scarfone G, Stoot J, Teodorovic I, Coens C, Vergote I, Vermorken J. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer GroupAnn Oncol 2003; 14: 441–448. Ann Oncol 2003. [DOI: 10.1093/annonc/mdg221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
van Wijk FH, Aapro MS, Bolis G, Chevallier B, van der Burg MEL, Poveda A, de Oliveira CF, Tumolo S, Scotto di Palumbo V, Piccart M, Franchi M, Zanaboni F, Lacave AJ, Fontanelli R, Favalli G, Zola P, Guastalla JP, Rosso R, Marth C, Nooij M, Presti M, Scarabelli C, Splinter TAW, Ploch E, Beex LVA, ten Bokkel Huinink W, Forni M, Melpignano M, Blake P, Kerbrat P, Mendiola C, Cervantes A, Goupil A, Harper PG, Madronal C, Namer M, Scarfone G, Stoot JEGM, Teodorovic I, Coens C, Vergote I, Vermorken JB. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003; 14:441-8. [PMID: 12598351 DOI: 10.1093/annonc/mdg112] [Citation(s) in RCA: 175] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Combination chemotherapy yields better response rates which do not always lead to a survival advantage. The aim of this study was to investigate whether the reported differences in the efficacy and toxicity of monotherapy with doxorubicin (DOX) versus combination therapy with cisplatin (CDDP) in endometrial adenocarcinoma lead to significant advantage in favour of the combination. PATIENTS AND METHODS Eligible patients had histologically-proven advanced and/or recurrent endometrial adenocarcinoma and were chemo-naïve. Treatment consisted of either DOX 60 mg/m(2) alone or CDDP 50 mg/m2 added to DOX 60 mg/m2, every 4 weeks. RESULTS A total of 177 patients were entered and median follow-up is 7.1 years. The combination DOX-CDDP was more toxic than DOX alone. Haematological toxicity consisted mainly of white blood cell toxicity grade 3 and 4 (55% versus 30%). Non-haematological toxicity consisted mainly of grade 3 and 4 alopecia (72% versus 65%) and nausea/vomiting (36 % versus 12%). The combination DOX-CDDP provided a significantly higher response rate than single agent DOX (P <0.001). Thirty-nine patients (43%) responded on DOX-CDDP [13 complete responses (CRs) and 26 partial responses (PRs)], versus 15 patients (17%) on DOX alone (8 CR and 7 PR). The median overall survival (OS) was 9 months in the DOX-CDDP arm versus 7 months in the DOX alone arm (Wilcoxon P = 0.0654). Regression analysis showed that WHO performance status was statistically significant as a prognostic factor for survival, and stratifying for this factor, treatment effect reaches significance (hazard ratio = 1.46, 95% confidence interval 1.05-2.03, P = 0.024). CONCLUSIONS In comparison to single agent DOX, the combination of DOX-CDDP results in higher but acceptable toxicity. The response rate produced is significantly higher, and a modest survival benefit is achieved with this combination regimen, especially in patients with a good performance status.
Collapse
|
9
|
van Wijk FH, Lhommé C, Bolis G, Scotto di Palumbo V, Tumolo S, Nooij M, de Oliveira CF, Vermorken JB. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. Eur J Cancer 2003; 39:78-85. [PMID: 12504662 DOI: 10.1016/s0959-8049(02)00504-x] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The aim of this study was to investigate the efficacy and toxicity of carboplatin given as monotherapy in endometrial adenocarcinoma. Cisplatin is one of the most active drugs in gynaecological cancer types, but at the cost of an associated high toxicity. In this high-risk population of endometrial cancer patients, it is necessary to have chemotherapy regimens with a low toxicity. Patients eligible for this study were those with histologically-confirmed endometrial adenocarcinoma with evidence of recurrent and/or metastatic disease. Carboplatin was administered every 4 weeks as a first- (dose: 400 mg/m(2)) or second- (dose: 300 mg/m(2)) line chemotherapy. Of the 64 patients who entered the trial, 60 were eligible, 53 patients were evaluable for toxicity and 47 for efficacy. A total of 169 cycles of carboplatin was given with a median of 2 cycles per patient (range 1-11 cycles) to a median cumulative dose of 798 mg/m(2) (range 290-3879 mg/m(2)). No grade 4 toxicity or toxic deaths occurred. White Blood Cell (WBC) toxicity grade 3 was noted five times, mainly in the radiotherapy pre-treated patients. Grade 3 non-haematological toxicity consisted mainly of nausea and vomiting (21%). There was a total of eight responses (3 Complete Responses (CR) and 5 Partial Responses (PR) with an overall response rate (ORR) of 13% (95% Confidence Interval (CI) 6-25). No responses occurred in patients treated with prior chemotherapy. In evaluable patients, the ORR in all patients (n=47) and in those receiving first-line chemotherapy (n=33) were, 17% (95% CI 8-31) and 24% (95% CI 11-42), respectively. After a median follow-up of 379 days, the median duration of response was 488 days (range 141-5303 days) with two very long responses in patients with a CR. Carboplatin has a low toxicity and is active in chemotherapy-naive advanced endometrial carcinoma patients. These results lead us to propose its use in association in first-line chemotherapy in recurrent or advanced endometrial carcinoma patients. The choice of the initial dose can be determined according to whether the patients have received prior radiotherapy treatment.
Collapse
|
10
|
Hamilton A, Biganzoli L, Coleman R, Mauriac L, Hennebert P, Awada A, Nooij M, Beex L, Piccart M, Van Hoorebeeck I, Bruning P, de Valeriola D. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. Ann Oncol 2002; 13:910-8. [PMID: 12123337 DOI: 10.1093/annonc/mdf157] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND We performed a phase I study of polyethylene glycol (pegylated, Stealth) liposomal doxorubicin (Caelyx, Doxil) using a prolonged (6-week) dose interval to reduce the incidence of skin toxicity that was dose-limiting at more conventional dose intervals, and which appeared to be schedule dependent. PATIENTS AND METHODS Eligible for the study were metastatic breast cancer patients who had received a maximum of one prior therapy for metastatic disease. The defined dose levels were 60, 70, 80 and 90 mg/m2. RESULTS Twenty patients were assessed at starting doses of 60 mg/m2 (n = 9) or 70 mg/m2 (n = 11). The dose-limiting toxicity was mucositis. Severe skin toxicity was not observed at the 60 mg/m2 dose level, and occurred in only one patient treated at 70 mg/m2. Significant neutropenia, alopecia, and nausea and vomiting were rare events. No clinical cardiac events occurred, despite a median cumulative doxorubicin dose of 323 mg/m2 (range 5-630 mg/m2). Partial responses were documented in five patients. Pharmacokinetics were assessed in 15 patients, and confirmed the long terminal half-life of the agent (median 77 h) demonstrated in earlier studies. CONCLUSIONS The recommended dose of Caelyx/Doxil using this schedule is 60 mg/m2 every 6 weeks. This is a safe and effective regimen that permits prolonged administration of anthracycline to patients with metastatic breast cancer.
Collapse
|
11
|
Awada A, Biganzoli L, Cufer T, Beex L, Lohrisch C, Batter V, Hamilton A, Nooij M, Piccart M. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes. Eur J Cancer 2002; 38:773-8. [PMID: 11937310 DOI: 10.1016/s0959-8049(01)00427-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The aim of this study was to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and potential activity of combined gemcitabine and continuous infusion 5-fluorouracil (5-FU) in metastatic breast cancer (MBC) patients that are resistant to anthracyclines or have been pretreated with both anthracyclines and taxanes. 15 patients with MBC were studied at three European Organization for Research and Treatment of Cancer centres. 13 patients had received both anthracylines and taxanes. Gemcitabine was given intravenously (i.v.) on days 1 and 8, and 5-FU as a continuous i.v. infusion on days 1 through to 14, both drugs given in a 21-day schedule at four different dose levels. Both were given at doses commonly used for the single agents for the last dose level (dose level 4). One of 6 patients at level 4 (gemcitabine 1200 mg/m2 and 5-FU 250 mg/m2/day) had a DLT, a grade 3 stomatitis and skin toxicity. One DLT, a grade 3 transaminase rise and thrombosis, occurred in a patient at level 2 (gemcitabine 1000 mg/m2 and 5-FU 200 mg/m2/day). Thus, the MTD was not reached. One partial response and four disease stabilisations were observed. Only 1 patient withdrew from the treatment due to toxicity. The MTD was not reached in the phase I study. The combination of gemcitabine and 5-FU is well tolerated at doses up to 1200 mg/m2 given on days 1 and 8 and 250 mg/m2/day given on days 1 through to 14, respectively, every 21 days. The clinical benefit rate (responses plus no change of at least 6 months) was 33% with one partial response, suggesting that MBC patients with prior anthracycline and taxane therapy may derive significant benefit from this combination with minimal toxicity.
Collapse
Affiliation(s)
- A Awada
- Jules Bordet Institute, Chemotherapy Unit, Bd de Waterloo 125, 1000 Brussels, Belgium.
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Paridaens R, Dirix L, Beex L, Nooij M, Cufer T, Lohrisch C, Biganzoli L, Van Hoorebeeck I, Duchateau L, Lobelle JP, Piccart M. Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control. Clin Breast Cancer 2000; 1 Suppl 1:S19-21. [PMID: 11970745 DOI: 10.3816/cbc.2000.s.004] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Because tamoxifen (TAM), a nonsteroidal antiestrogen, is routinely used in the adjuvant setting, other hormone therapies are needed as alternatives for first-line treatment of metastatic breast cancer (MBC). Currently, exemestane (EXE) and other antiaromatase agents are indicated for use in patients who experience failure of TAM. In this multicenter, randomized, open-label, TAM-controlled (20 mg/day), phase II trial, we examined the activity and tolerability of EXE 25 mg/day for the first-line treatment of MBC in postmenopausal women. Exemestane was well tolerated and demonstrated substantial first-line antitumor activity based on intent-to-treat analysis of peer-reviewed responses. In the EXE arm, values for complete, partial, and objective response, clinical benefit, and time to tumor progression (TTP) exceeded those reported for TAM although no statistical comparison was made. Based on these encouraging results, a phase III trial will compare EXE and TAM.
Collapse
Affiliation(s)
- R Paridaens
- Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
ten Asbroek AL, Fluiter K, van Groenigen M, Nooij M, Baas F. Polymorphisms in the large subunit of human RNA polymerase II as target for allele-specific inhibition. Nucleic Acids Res 2000; 28:1133-8. [PMID: 10666454 PMCID: PMC102615 DOI: 10.1093/nar/28.5.1133] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The lack of specificity of cancer treatment causes damage to normal cells as well, which limits the therapeutic range. To circumvent this problem one would need to use an absolute difference between normal cells and cancer cells as therapeutic target. Such a difference exists in the genome of all individuals suffering from a tumor that is characterized by loss of genetic material [loss of heterozygosity (LOH)]. Due to LOH, the tumor is hemizygous for a number of genes, whereas the normal cells of the individual are heterozygous for these genes. Theoretically, polymorphic sites in these genes can be utilized to selectively target the cancer cells with an antisense oligonucleotide, provided that it can discriminate the alleles and inhibit gene expression. Furthermore, the targeted gene should be essential for cell survival, and 50% gene expression sufficient for the cell to survive. This will allow selective killing of cancer cells without concomitant toxicity to normal cells. As an initial step in the experimental test of this putative selective cancer cell therapy, we have developed a set of antisense phosphorothioate oligonucleotides which can discriminate the two alleles of a polymorphic site in the gene encoding the large subunit of RNA polymerase II. Our data show that the exact position of the antisense oligonucleotide on the mRNA is of essential importance for the oligo-nucleotide to be an effective inhibitor of gene expression. Shifting the oligonucleotide position only a few bases along the mRNA sequence will completely abolish the inhibitory activity of the antisense oligonucleotide. Reducing the length of the oligonucleotides to 16 bases increases the allele specificity. This study shows that it is possible to design oligonucleotides that selectively target the matched allele, whereas the expression level of the mismatched allele, that differs by one nucleotide, is only slightly affected.
Collapse
Affiliation(s)
- A L ten Asbroek
- Neurozintuigen Laboratory, Academic Medical Center, PO Box 22700, 1000 DE Amsterdam, The Netherlands
| | | | | | | | | |
Collapse
|
14
|
Bramwell VH, Steward WP, Nooij M, Whelan J, Craft AW, Grimer RJ, Taminau AH, Cannon SR, Malcolm AJ, Hogendoorn PC, Uscinska B, Kirkpatrick AL, Machin D, Van Glabbeke MM. Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European Osteosarcoma Intergroup study. J Clin Oncol 1999; 17:3260-9. [PMID: 10506628 DOI: 10.1200/jco.1999.17.10.3260] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Studies involving small case series have suggested that malignant fibrous histiocytoma of bone (MFH-B) is a chemosensitive tumor and that chemotherapy may improve survival. In this study, we evaluated clinical and pathologic response rates and survival in a series of patients treated with a consistent chemotherapy regimen of doxorubicin and cisplatin (DOX/DDP). PATIENTS AND METHODS Study patients were required to have biopsy-proven MFH-B, no previous chemotherapy, and primary or metastatic measurable disease and to be </= 65 years of age. Treatment consisted of doxorubicin 25 mg/m(2)/d days 1 through 3 and cisplatin 100 mg/m(2) by 4-hour intravenous infusion every 3 weeks for six cycles. In patients with operable primary tumors, chemotherapy was planned to start within 42 days of biopsy, with definitive surgery performed after three cycles. RESULTS Forty-one patients had operable nonmetastatic limb sarcomas, and 23 (56%) completed six chemotherapy cycles. Limb salvage was possible in 33 patients (80%), and 16 (42%) of 38 assessable specimens showed a good pathologic response (>/= 90% necrosis). Median time to progression was 56 months, and the 5-year progression-free survival rate was 56% (95% confidence interval [CI], 40% to 72%). Median survival time was 63 months, and the 5-year survival rate was 59% (95% CI, 41% to 77%). Patients with a good pathologic response had longer survival times and times to progression than did those with a poor response. Also treated were two patients with locally recurrent and nine with metastatic disease, and these patients had a median survival time of 17.5 months. CONCLUSION Our study suggests that adjuvant or neoadjuvant chemotherapy with DOX/DDP is beneficial in MFH-B. Good pathologic response rates and survivals are quite comparable with those for osteosarcoma, a related bone tumor for which adjuvant or neoadjuvant chemotherapy is an accepted practice.
Collapse
Affiliation(s)
- V H Bramwell
- London Regional Cancer Centre, London, Ontario, Canada.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Voûte PA, Souhami RL, Nooij M, Somers R, Cortés-Funes H, van der Eijken JW, Pringle J, Hogendoorn PC, Kirkpatrick A, Uscinska BM, van Glabbeke M, Machin D, Weeden S. A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI). Ann Oncol 1999; 10:1211-8. [PMID: 10586339 DOI: 10.1023/a:1008361612767] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Despite advances in the treatment of primary limb osteosarcoma, the outcome of patients with primary metastatic and axial skeletal disease remains poor. The European Osteosarcoma Intergroup have assessed a combination chemotherapy regimen consisting of ifosfamide (IFOS) 3 g/m2/dl-2, doxorubicin (DOX) 25 mg/m2/dl-3 i.v. bolus and cisplatin (CDDP) 100 mg/m2/dl. PATIENTS AND METHODS One hundred nine previously untreated patients with primary osteosarcoma were registered. Eligibility was confirmed in 103. At presentation, 45 eligible patients had metastatic disease, 15 axial skeletal primary tumours and 43 non-metastatic limb tumours. RESULTS The major toxicities were myelosuppression (90%, grade 3 or 4) and nausea and vomiting (74%, grade 3 or 4). Overall mean relative dose intensity (RDI) was 80% (88% CDDP, 75% IFOS, 81% DOX). Clinical response as measured by reduction in tumour volume occurred in 36% (95% confidence interval (95% CI): 27%-47%) of primary tumours. Response of pulmonary metastases to chemotherapy was seen in 33% (95% CI: 19%-49%). Good histological response (> or = 90% necrosis of the tumour) occurred in 33% (95% CI: 22%-45%) of resected tumours. Five-year survival was 62% in limb-non-metastatic, 41% in axial skeletal and 16% in limb metastatic patients. CONCLUSIONS This regimen is active in osteosarcoma but does not appear to be more active than the two-drug CDDP-DOX regimen currently recommended by EOI.
Collapse
Affiliation(s)
- P A Voûte
- Emma Kinderziekenhuis, Academic Medical Center, Amsterdam, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Awada A, Cufer T, Beex L, Coleman R, Paridaens R, Bruning P, Klijn J, Nooij M, Mauriac L, Van Vreckem A, Biganzoli L, Piccart M. EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): Seven years of active European collaboration. Eur J Cancer 1998. [DOI: 10.1016/s0959-8049(98)80083-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
17
|
Bruning PF, Bonfrer JM, Paridaens R, Nooij M, Klijn JG, Beex LV, Bruynseels J, Piccart MJ. Vorozole (R83842) in the treatment of postmenopausal advanced breast cancer: relationship of serum levels of vorozole and clinical results (a study of the EORTC Breast Cancer Cooperative Group). Anticancer Drugs 1998; 9:419-25. [PMID: 9660539 DOI: 10.1097/00001813-199806000-00008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The new non-steroidal aromatase inhibitor vorozole (R83842) was administered orally at a single daily dose of 2.5 mg to 27 postmenopausal women with advanced breast cancer in a phase II trial as second-line endocrine treatment. The observed objective response rate of 30% and good tolerability of the drug confirm other recent reports. Endocrine determinations during 6 months of treatment demonstrated reduction of serum estrogens: estrone sulfate by more than 60%, estrone by 30-40%, but estradiol by only 10-20%. The ratios of serum androstenedione/estrone and testosterone/estradiol increased significantly, consistent with the inhibition of peripheral aromatase activity. Levels of progesterone, 17-alpha-hydroxyprogesterone, cortisol, dehydroepiandrosterone sulfate, androstenedione and aldosterone remained normal, indicating no interference with adrenocortical steroid synthesis. A general lack of correlation between the observed serum concentrations of vorozole and its effect on hormone serum levels or clinical response was found. This suggests that the determination of such serum levels gives a poor impression of the unambiguous anti-tumor activity of vorozole which may well have its main effect with the tumor tissue itself. The present results are in support of aromatase inhibition, but the possibility of an additional effect on the sulfation of estrogens merits further investigation.
Collapse
Affiliation(s)
- P F Bruning
- Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Paridaens R, Roy JA, Nooij M, Klijn J, Houston SJ, Beex LV, Vinholes J, Tomiak E, Van Vreckem A, Langenaeken C, Van Glabbeke M, Piccart MJ. Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group. Anticancer Drugs 1998; 9:29-35. [PMID: 9491789 DOI: 10.1097/00001813-199801000-00003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Vorozole (Rivizor) is a potent and stereospecific inhibitor of aromatase having shown promising endocrine effects in phase I studies. In the present trial, 27 postmenopausal patients with advanced breast cancer, measurable lesions, presumably hormone responsive (ER or PR+, or ER? with disease-free survival longer than 1 year, or prior documented response to tamoxifen), were treated with vorozole one tablet 2.5 mg daily. All had been previously treated with tamoxifen as adjuvant (two patients) or for advanced disease (24 patients), or both (one patient). Objective remissions were observed in eight patients (30%) with two complete responses (CR) and six partial responses (PR) lasting for a median of 14.3 months (range 6.8-40.6); nine stabilizations were also recorded (median 7.9 months; range 3.7-40.1). Median time to progression for the 27 patients was 5.9 months. Sites of response were skin (three patients), lymph nodes (two patients), lung (two patients) and chest wall plus lymph nodes (one patient). Treatment was very well tolerated: mild hot flushes (four patients), gastrointestinal complaints (four patients) and no significant toxicity (common toxicity criteria grade above 2) or drug-related severe adverse event. It is concluded that vorozole is an active second-line endocrine treatment, deserving consideration for randomized comparison with other agents such as aminoglutethimide, megestrol acetate or medroxyprogesterone acetate.
Collapse
Affiliation(s)
- R Paridaens
- University Hospital Gasthuisberg, Leuven, Belgium
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH, Wierzbicki R, Malcolm AJ, Kirkpatrick A, Uscinska BM, Van Glabbeke M, Machin D. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997; 350:911-7. [PMID: 9314869 DOI: 10.1016/s0140-6736(97)02307-6] [Citation(s) in RCA: 302] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND A previous trial by the European Osteosarcoma Intergroup (EOI) suggested that a short intensive chemotherapy regimen with doxorubicin and cisplatin might produce survival of operable, non-metastatic osteosarcoma similar to that obtained with complex and longer-duration drug regimens based on the widely used T10 multi-drug protocol. We undertook a randomised multicentre trial to compare these two approaches. METHODS 407 patients with operable, non-metastatic osteosarcoma were randomly assigned the two-drug regimen (six cycles [18 weeks] of doxorubicin 25 mg/m2 on days 1-3 and cisplatin 100 mg/m2 on day 1) or a multi-drug regimen (preoperatively vincristine, high-dose methotrexate, and doxorubicin; postoperatively bleomycin, cyclophosphamide, dactinomycin, vincristine, methotrexate, doxorubicin, and cisplatin; this protocol took 44 weeks). Surgery was scheduled for week 9 for the two-drug group and week 7 for the multi-drug group. Analyses of survival and progression-free survival were by intention to treat. FINDINGS Of 407 randomised patients, 391 were eligible and have been followed up for at least 4 years (median 5-6 years). Toxic effects were qualitatively similar with the two regimens. However, 188 (94%) of 199 patients completed the six cycles of two-drug treatment, whereas only 97 (51%) of 192 completed 18 or more of the 20 cycles of the multi-drug regimen. The proportion showing a good histopathological response (> 90% tumour necrosis) to preoperative chemotherapy was about 29% with both regimens and was strongly predictive of survival. Overall survival was 65% at 3 years and 55% at 5 years in both groups (hazard ratio 0.94 [95% CI 0.69-1.27]). Progression-free survival at 5 years was 44% in both groups (hazard ratio 1.01 [0.77-1.33]). INTERPRETATION We found no difference in survival between the two-drug and multi-drug regimens in operable, non-metastatic osteosarcoma. The two-drug regimen is shorter in duration and better tolerated, and is therefore the preferred treatment. However, 5-year survival is still unsatisfactory and new approaches to treatment, such as dose intensification, are needed to improve results.
Collapse
Affiliation(s)
- R L Souhami
- University College London Medical School, UK
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997; 15:3149-55. [PMID: 9294478 DOI: 10.1200/jco.1997.15.9.3149] [Citation(s) in RCA: 115] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
PURPOSE To confirm the efficacy of docetaxel in patients with breast cancer previously treated with one chemotherapy regimen for advanced or metastatic disease and to compare the incidence of fluid retention (FR) and skin toxicity when docetaxel is administered with and without prophylactic corticosteroids. PATIENTS AND METHODS Eighty-three patients, pretreated with one chemotherapy regimen for metastatic breast cancer (MBC) with bidimensionally measurable and progressive disease, were eligible for this randomized trial. Docetaxel with prophylactic oral antihistamine was administered at a dose of 50 mg/m2 as a 1-hour infusion on days 1 and 8 every 21 days and patients were randomized to receive methylprednisolone (40 mg days -1, 0, 1, 7, 8, and 9 of each cycle) (arm A) or no methylprednisolone (arm B). RESULTS Twenty-eight patients (34%, 95% confidence interval [CI], 23% to 45%) achieved on objective response. The median time to disease progression and median overall survival time were 5 and 13.5 months, respectively. In total, 415 cycles of docetaxel were administered (arm A: N = 219, median = six; arm B: N = 196, median = five). The most common toxicity observed was grade 3 or 4 neutropenia, which occurred in 79% of patients. Clinically significant nonhematologic side effects included skin reactions and asthenia. In an intent-to-treat analysis, patients who received methylprednisolone premedication had a delayed onset of FR (median time to onset of FR: arm A, 84 days; arm B, 62 days; P = .01) and received a higher median cumulative dose of docetaxel before the onset of FR (arm A, 333 mg/m2; arm B, 215 mg/m2; P = .001). There was no statistically significant difference in the incidence of skin toxicity between the two arms. CONCLUSION Docetaxel, at this dose and schedule, has definite antitumor activity in pretreated MBC patients. Moreover, this is the first randomized trial to show that corticosteroids have a favorable impact on docetaxel-induced FR.
Collapse
Affiliation(s)
- M J Piccart
- Jules Bordet Institute, Chemotherapy Unit, Brussels, Belgium.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Guastalla JP, Vermorken JB, Wils JA, George M, Scotto V, Nooij M, ten Bokkel Huinnink WW, Dalesio O, Renard J. Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy--a phase II study of the EORTC Gynaecological Cancer Cooperative Group. Eur J Cancer 1994; 30A:45-9. [PMID: 8142163 DOI: 10.1016/s0959-8049(05)80017-6] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
On the basis of its efficacy against ovarian carcinoma and its safe peritoneal administration, cisplatin administered by the intraperitoneal route was studied in a phase II multicentric trial. 34 patients with good performance status and residual disease less than 1 cm were treated with a 90 mg/m2 dose (60 mg/m2 at first cycle), administered in the abdominal cavity every 3 weeks for at least four cycles. In case of haematological or renal toxicity, intravenous sodium thiosulphate was perfused simultaneously with intraperitoneal cisplatin with protective intent. 25 patients were evaluable for response: 3 patients had pathological complete response and 1 patient had a microscopic disease (16% response rate in evaluable patients). Systemic toxicity was mild, and sodium thiosulphate clearly protected against leucopenia (6 patients) and renal toxicity (8 patients). Local side-effects were evaluable in 34 patients with 2 cases of infectious peritonitis, 1 of wound infection and 2 of haemorrhage. Of the 147 evaluable chemotherapy cycles, nine resulted in partial and one in total inflow obstruction, for which 4 patients needed surgical procedures for catheter-related complications, and 1 patient died of acute abdominal complications after such a procedure. We conclude that 90 mg/m2 intraperitoneal cisplatin has activity in pretreated patients with minimal residual disease, and that thiosulphate protects against haematological and renal toxicities. Only a randomised study can demonstrate a true benefit, which will have to be balanced with the toxicity of intraperitoneal drug administration.
Collapse
Affiliation(s)
- J P Guastalla
- Département de Médecine Oncologique, Centre Léon Bérard, Lyon, France
| | | | | | | | | | | | | | | | | |
Collapse
|